Archived explainer. For the current picture see today's LEGN page.
LEGEND BIOTECH CORP ADR (LEGN) is down -13.28% in the latest session. Our newswire has captured 11 stories on LEGN across 8 sources in the last 36 hours, with AI sentiment reading mixed (avg 45/100).
Legend Biotech Corp ADR (LEGN) fell 13.28% to $19.27 in afternoon trading on July 27, 2026, following the unexpected resignation of CEO Ying Huang. The stock opened with a 2.6% gap down and continued to decline throughout the session, reaching a low of $18.64. The leadership change has raised concerns among investors about the company’s strategic direction and operational continuity.
Legend Biotech announced that Ying Huang, Ph.D., has stepped down as CEO and board member, effective July 24. Alan Bash was appointed as interim CEO. Huang cited his intention to pursue an opportunity at an early-stage venture company. During a sell-side call, he expressed confidence in the company’s strategy and long-term growth opportunities. The board emphasized continuity and stability in its messaging, stating that Bash is well-positioned to lead the company through the transition. Raymond James and RBC both cut their price targets for the stock, with RBC lowering it to $59 on model updates. UBS and JPMorgan also adjusted their ratings to Neutral, with price targets of $28 and $35 respectively.
The stock has declined 15.7% over the last eight sessions, from $22.71 to $19.15. The current price of $19.27 is within the 52-week range of $16.24 to $44.78. The company has a market capitalization of $4.3 billion and remains unprofitable, with a trailing twelve-month earnings per share of -1.38 and a net margin of -22.0%. Revenue has grown 56.4% over the same period. Insider transactions in the last 90 days include two sales totaling $171,000, with the most recent filing on July 2. The stock traded 8.7 million shares so far in the session, more than three times the 3-month average.
Investors should monitor the company’s upcoming developments, including any changes in strategic direction under the new interim leadership. Analyst coverage and price target adjustments may continue to influence the stock’s performance in the coming weeks.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
Legend said on Monday that Ying Huang stepped down as chief executive officer and board member effective July 24.
Huang said he will be pursuing an opportunity at an early-stage venture company, but remains confident in Legend's strategy, pipeline and long-term growth opportunities during a sell-side call, Morgan Stanley analysts said in a note.
Legend Biotech has announced a CEO change, appointing Alan Bash as interim CEO after Ying Huang, Ph.D., steps down. The company, a leader in cell therapy, emphasizes stability and continuity amid the leadership shift, while confirming ongoing commitment to its growth strategy and innovation in CAR-T therapies.
Raymond James cuts Legend Biotech stock price target on CEO departure
RBC cuts Legend Biotech stock price target to $59 on model updates
Why is Legend Biotech stock sliding today?
Legend Biotech stock falls as CEO Ying Huang steps down
Legend Biotech announces a change in leadership as Ying Huang, Ph.D., steps down as CEO, with Alan Bash appointed Interim CEO. The company underscores stability and a commitment to advancing its pioneering cell therapies amid the executive transition. Here’s what the leadership change means for the future of Legend Biotech and its pipeline.
More on LEGN: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier LEGN move explainers: 2026-07-28 · 2026-07-27